Drug Trial Radar · NCT06970782
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
278
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Avistone Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure
Conditions
- Non-Small-Cell Lung Cancer
Interventions
VebreltinibDrug
Subjects will receive Vebreltinib Enteric-coated Capsule orally twice per day (BID).
PLB1004Drug
Subjects will receive PLB1004 80mg orally once per day (QD).
Pemetrexed plus Carboplatin or CisplatinDrug
Subjects randomized to the control group received pemetrexed 500 mg/m² + platinum-based chemotherapy (carboplatin AUC 5 or cisplatin 75 mg/m²) via intravenous infusion for 4-6 cycles (determined by the investigator) as initial therapy, followed by pemetrexed maintenance therapy (500 mg/m²) until disease progression, intolerable toxicity, initiation of new antitumor therapy, death, loss to follow-up, or other treatment-terminating conditions (whichever occurred first).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by BICRTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.